Here, we show that responses to ICB-based therapy in R/R AML are associated with expansions and novel emergence of CD8 + T-cell clonotypes while resistance to this therapy is associated with contracted T-cell clonotypes. Here, CD8A is linked to acute myeloid leukemia.